Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Plandaí Biotechnology, Inc. (PLPL) Initiates Clinical Trials For Phytofare Topical Product

|Includes: Plandai Biotechnology, Inc. (PLPL)

Plandaí Biotechnology, developer of bioavailable plant extracts used in the health, wellness, nutraceutical, and pharmaceutical industries, reports that North-West University, a leading medical research facility in Potchefstroom, South Africa, will conduct several clinical studies involving the Phytofare™ Pheroid™ Topical Catechin Complex ("ph2TM"), a new topical cream based on the nano-entrapment technology developed by NWU professor Anne Grobler.

The first of two studies, initiated last month, is testing the moisturizing effects of ph2TM on 35 human volunteers. A second study, also commenced last month on 35 human subjects, is testing the anti-inflammatory benefits of the product. A third human study slated to start later in the year will explore the anti-aging properties of the topical cream.

ph2TM was recently licensed to PLPL for human and animal use and is expected to be marketed as an ingredient in a variety of skin care products.

"We are enthusiastic about the potential for ph2TM Topical Catechin Complex in the nutriceutical market space," Roger Duffield, chairman and CEO of PLPL stated in the press release. "We've fielded multiple inquiries from large skin care product manufacturers interested in seeing the known benefits of green tea catechins transferred into a topical solution that can penetrate through the various tissue levels and be absorbed at the cellular level. We envision this product being incorporated into products ranging from skin rejuvenation to anti-aging to after shave."

The studies for the new topical cream are expected to take roughly three months leading up to anticipated market release during the first quarter of 2014.

For more information, visit plandaibiotech.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net